论文部分内容阅读
一线酪氨酸激酶抑制剂(TKI)给慢性髓细胞白血病(CML)的治疗带来了革命性进步。但长期应用TKI所带来的毒副作用、经济负担、CML干细胞的残留等问题,给TKI的临床应用带来了挑战。TKI的耐药问题也成为了目前CML研究中的热点。自噬是一种细胞面临营养缺乏或者应激状态时的自我保护机制。近年来越来越多的研究提示,自噬在CML细胞增殖、TKI耐药等过程中发挥重要作用。本文就目前自噬(这里指巨自噬)
First-line tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myelogenous leukemia (CML). However, long-term use of TKI brought about the side effects, economic burden, residual CML stem cells and other issues, to the clinical application of TKI posed a challenge. TKI drug resistance has also become a hot topic in the current CML research. Autophagy is a cell self-protection mechanism in the face of nutritional deficiencies or stress conditions. In recent years, more and more studies suggest that autophagy plays an important role in CML cell proliferation, TKI resistance and other processes. This article on the current autophagy (here refers to the giant autophagy)